Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T14:38:45.519Z Has data issue: false hasContentIssue false
  • English
  • Français

The Thermostability of Vaccines: Technologies for Improving the Thermostability of the Oral Poliovirus Vaccine

Published online by Cambridge University Press:  14 October 2009

Stanley M. Lemon  and
Julie B. Milstien
Stanley M. Lemon
Affiliation:
University of North Carolina, Chapel Hill
Julie B. Milstien
Affiliation:
World Health Organization
Get access Rights & Permissions [Opens in a new window]

Abstract

Technologies that promise to enhance the stability of vaccines are likely to be determined by the product-specific physical structure and biological functions of the specific vaccine immunogens. Research may define the extent to which the stability of oral poliovirus vaccine may be improved by the addition of certain antiviral components that bind to the poliovirus capsid or by the application of novel drying technologies.

Type
Special Section: Vaccines and Public Health: Assessing Technologies and Public Policies
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 1 , Winter 1994 , pp. 177 - 184
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Andries, K., Dewindt, B., Snoeks, J., et al. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. Journal of Virology, 1990, 64, 1117–23.Google Scholar
2.Colaco, C., Sen, S., Thangavelu, M., et al. Extraordinary stability of enzymes dried in trehalose: Simplified molecular biology. Bio/Technology, 1992, 10, 1007–11.Google ScholarPubMed
3.Galazka, A.Stability of vaccines. Geneva, Switzerland: World Health Organization, WHO/EPI/GEN/89.8.Google Scholar
4.Global Advisory Group. Expanded Programme on Immunization. Report of the 15th Global Advisory Group. Geneva, Switzerland: World Health Organization, WHO/EPI/GEN/92.Google Scholar
5.Hayden, F. G., Andries, K., & Janssen, P. A. J.Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrobial Agents and Chemotherapy, 1992, 36, 727–32.Google Scholar
6.Hogle, J. M., Chow, M., & Filman, D. J.Three-dimensional structure of poliovirus at 2.9Å resolution. Science, 1985, 229, 1358–65.CrossRefGoogle Scholar
7.Lemon, S. M., & Robertson, S. E.Global eradication of poliomyelitis: Recent progress, future prospects, and new research priorities. Progress in Medical Virology, 1991, 38, 42–55.Google Scholar
8.Macadam, A. J., Ferguson, G., Burlison, J., et al. Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in fissue culture. Virology, 1992, 189, 415–22.Google Scholar
9.Macadam, A. J., Pollard, S. R., Ferguson, G., et al. The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology, 1991, 181, 451–58.Google Scholar
10.McSharry, J. J., Caliguiri, L. A., & Eggers, H. J.Inhibition of uncoating of poliovirus by arildone, a new antiviral drug. Virology, 1979, 97, 307–15.CrossRefGoogle ScholarPubMed
11.Melnick, J. L., & Wallis, C.Effects of pH on thermal stabilization of oral poliovirus vaccine by magnesium chloride. Proceedings of the Society for Experimental Biology and Medicine, 1963, 112, 894–97.CrossRefGoogle ScholarPubMed
12.Mendelsohn, C. L., Wimmer, E., & Racaniello, V. R.Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immuno-globulin superfamily. Cell, 1989, 56, 855–65.Google Scholar
13.Molla, A., Paul, A. V., & Wimmer, E.Cell-free, do novo synthesis of poliovirus. Science, 1991, 254, 1647–51.CrossRefGoogle ScholarPubMed
14.Moss, E. G., O'Neill, R. E., & Racaniello, V. R.Mapping of attenuating sequences of an avirulent poliovirus type 2 strain. Journal of Virology, 1989, 63, 1884–90.CrossRefGoogle ScholarPubMed
15.Omata, T., Kohara, M., Kuge, S., et al. Genetic analysis of the attenuation phenotype of poliovirus type 1. Journal of Virology, 1986, 58, 348–58.CrossRefGoogle ScholarPubMed
16.Patriarca, P. A., Wright, P. F., & John, T. J.Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Reviews of Infectious Diseases, 1991, 13, 926–39.Google Scholar
17.Pevear, D. C., Fancher, M. J., Felock, P. J., et al. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. Journal of Virology, 1989, 63, 2002–07.CrossRefGoogle ScholarPubMed
18.Racaniello, V. R., & Baltimore, D.Cloned poliovirus complementary DNA is infectious in mammalian cells. Science, 1981, 214, 916–19.Google Scholar
19.Rombaut, B., Andries, K., & Boeye, A.A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids. Journal of General Virology, 1991, 72, 2153–57.Google Scholar
20.Sabin, A. B.Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world. Journal of Infectious Diseases, 1985, 151, 420–36.Google Scholar
21.Smith, T. J., Kremer, M. J., Luo, M., et al. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science, 1986, 233, 1286–93.CrossRefGoogle ScholarPubMed
22.Tatem, J. M., Weeks-Levy, C., Georgiu, A., et al. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. Journal of Virology, 1992, 66, 3194–97.Google Scholar
23.Wright, P. F., Kim-Farley, R. J., de Quadros, C., et al. Strategies of the global eradication of poliomyelitis by the year 2000. New England Journal of Medicine, 1991, 325, 1774–79.CrossRefGoogle ScholarPubMed